Apoptotic function of human PMS2 compromised by the nonsynonymous single-nucleotide polymorphic variant R20Q

Ivana Marinovic-Terzic, Atsuko Yoshioka-Yamashita, Hideki Shimodaira, Elena Avdievich, Irina C. Hunton, Richard D. Kolodner, Winfried Edelmann, Jean Y J Wang

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Mismatch repair (MMR) corrects replication errors during DNA synthesis. The mammalian MMR proteins also activate cell cycle checkpoints and apoptosis in response to persistent DNA damage. MMR-deficient cells are resistant to cisplatin, a DNA cross-linking agent used in chemotherapy, because of impaired activation of apoptotic pathways. It is shown that postmeiotic segregation 2 (PMS2), an MMR protein, is required for cisplatin-induced activation of p73, a member of the p53 family of transcription factors with proapoptotic activity. The human PMS2 is highly polymorphic, with at least 12 known nonsynonymous codon changes identified. We show here that the PMS2(R20Q) variant is defective in activating p73-dependent apoptotic response to cisplatin. When expressed in Pms2-deficient mouse fibroblasts, human PMS2(R20Q) but not PMS2 interfered with the apoptotic response to cisplatin. Correspondingly, PMS2 but not PMS2(R20Q) enhanced the cytotoxic effect of cisplatin measured by clonogenic survival. Because PMS2(R20Q) lacks proapoptotic activity, this polymorphic allele may modulate tumor responses to cisplatin among cancer patients.

Original languageEnglish (US)
Pages (from-to)13993-13998
Number of pages6
JournalProceedings of the National Academy of Sciences of the United States of America
Volume105
Issue number37
DOIs
StatePublished - Sep 16 2008

Fingerprint

Cisplatin
DNA Mismatch Repair
Nucleotides
DNA
Cell Cycle Checkpoints
Codon
DNA Damage
Neoplasms
Proteins
Transcription Factors
Fibroblasts
Alleles
Apoptosis
Drug Therapy
Survival

Keywords

  • Chemotherapy
  • Cisplatin
  • Mismatch repair
  • MLH1
  • p73

ASJC Scopus subject areas

  • General

Cite this

Marinovic-Terzic, I., Yoshioka-Yamashita, A., Shimodaira, H., Avdievich, E., Hunton, I. C., Kolodner, R. D., ... Wang, J. Y. J. (2008). Apoptotic function of human PMS2 compromised by the nonsynonymous single-nucleotide polymorphic variant R20Q. Proceedings of the National Academy of Sciences of the United States of America, 105(37), 13993-13998. https://doi.org/10.1073/pnas.0806435105

Apoptotic function of human PMS2 compromised by the nonsynonymous single-nucleotide polymorphic variant R20Q. / Marinovic-Terzic, Ivana; Yoshioka-Yamashita, Atsuko; Shimodaira, Hideki; Avdievich, Elena; Hunton, Irina C.; Kolodner, Richard D.; Edelmann, Winfried; Wang, Jean Y J.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 105, No. 37, 16.09.2008, p. 13993-13998.

Research output: Contribution to journalArticle

Marinovic-Terzic, Ivana ; Yoshioka-Yamashita, Atsuko ; Shimodaira, Hideki ; Avdievich, Elena ; Hunton, Irina C. ; Kolodner, Richard D. ; Edelmann, Winfried ; Wang, Jean Y J. / Apoptotic function of human PMS2 compromised by the nonsynonymous single-nucleotide polymorphic variant R20Q. In: Proceedings of the National Academy of Sciences of the United States of America. 2008 ; Vol. 105, No. 37. pp. 13993-13998.
@article{6dbd68a8054c4726b89a60e8ab39e8b0,
title = "Apoptotic function of human PMS2 compromised by the nonsynonymous single-nucleotide polymorphic variant R20Q",
abstract = "Mismatch repair (MMR) corrects replication errors during DNA synthesis. The mammalian MMR proteins also activate cell cycle checkpoints and apoptosis in response to persistent DNA damage. MMR-deficient cells are resistant to cisplatin, a DNA cross-linking agent used in chemotherapy, because of impaired activation of apoptotic pathways. It is shown that postmeiotic segregation 2 (PMS2), an MMR protein, is required for cisplatin-induced activation of p73, a member of the p53 family of transcription factors with proapoptotic activity. The human PMS2 is highly polymorphic, with at least 12 known nonsynonymous codon changes identified. We show here that the PMS2(R20Q) variant is defective in activating p73-dependent apoptotic response to cisplatin. When expressed in Pms2-deficient mouse fibroblasts, human PMS2(R20Q) but not PMS2 interfered with the apoptotic response to cisplatin. Correspondingly, PMS2 but not PMS2(R20Q) enhanced the cytotoxic effect of cisplatin measured by clonogenic survival. Because PMS2(R20Q) lacks proapoptotic activity, this polymorphic allele may modulate tumor responses to cisplatin among cancer patients.",
keywords = "Chemotherapy, Cisplatin, Mismatch repair, MLH1, p73",
author = "Ivana Marinovic-Terzic and Atsuko Yoshioka-Yamashita and Hideki Shimodaira and Elena Avdievich and Hunton, {Irina C.} and Kolodner, {Richard D.} and Winfried Edelmann and Wang, {Jean Y J}",
year = "2008",
month = "9",
day = "16",
doi = "10.1073/pnas.0806435105",
language = "English (US)",
volume = "105",
pages = "13993--13998",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
number = "37",

}

TY - JOUR

T1 - Apoptotic function of human PMS2 compromised by the nonsynonymous single-nucleotide polymorphic variant R20Q

AU - Marinovic-Terzic, Ivana

AU - Yoshioka-Yamashita, Atsuko

AU - Shimodaira, Hideki

AU - Avdievich, Elena

AU - Hunton, Irina C.

AU - Kolodner, Richard D.

AU - Edelmann, Winfried

AU - Wang, Jean Y J

PY - 2008/9/16

Y1 - 2008/9/16

N2 - Mismatch repair (MMR) corrects replication errors during DNA synthesis. The mammalian MMR proteins also activate cell cycle checkpoints and apoptosis in response to persistent DNA damage. MMR-deficient cells are resistant to cisplatin, a DNA cross-linking agent used in chemotherapy, because of impaired activation of apoptotic pathways. It is shown that postmeiotic segregation 2 (PMS2), an MMR protein, is required for cisplatin-induced activation of p73, a member of the p53 family of transcription factors with proapoptotic activity. The human PMS2 is highly polymorphic, with at least 12 known nonsynonymous codon changes identified. We show here that the PMS2(R20Q) variant is defective in activating p73-dependent apoptotic response to cisplatin. When expressed in Pms2-deficient mouse fibroblasts, human PMS2(R20Q) but not PMS2 interfered with the apoptotic response to cisplatin. Correspondingly, PMS2 but not PMS2(R20Q) enhanced the cytotoxic effect of cisplatin measured by clonogenic survival. Because PMS2(R20Q) lacks proapoptotic activity, this polymorphic allele may modulate tumor responses to cisplatin among cancer patients.

AB - Mismatch repair (MMR) corrects replication errors during DNA synthesis. The mammalian MMR proteins also activate cell cycle checkpoints and apoptosis in response to persistent DNA damage. MMR-deficient cells are resistant to cisplatin, a DNA cross-linking agent used in chemotherapy, because of impaired activation of apoptotic pathways. It is shown that postmeiotic segregation 2 (PMS2), an MMR protein, is required for cisplatin-induced activation of p73, a member of the p53 family of transcription factors with proapoptotic activity. The human PMS2 is highly polymorphic, with at least 12 known nonsynonymous codon changes identified. We show here that the PMS2(R20Q) variant is defective in activating p73-dependent apoptotic response to cisplatin. When expressed in Pms2-deficient mouse fibroblasts, human PMS2(R20Q) but not PMS2 interfered with the apoptotic response to cisplatin. Correspondingly, PMS2 but not PMS2(R20Q) enhanced the cytotoxic effect of cisplatin measured by clonogenic survival. Because PMS2(R20Q) lacks proapoptotic activity, this polymorphic allele may modulate tumor responses to cisplatin among cancer patients.

KW - Chemotherapy

KW - Cisplatin

KW - Mismatch repair

KW - MLH1

KW - p73

UR - http://www.scopus.com/inward/record.url?scp=52949143488&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=52949143488&partnerID=8YFLogxK

U2 - 10.1073/pnas.0806435105

DO - 10.1073/pnas.0806435105

M3 - Article

C2 - 18768816

AN - SCOPUS:52949143488

VL - 105

SP - 13993

EP - 13998

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 37

ER -